Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Durect Corporation

DRRX
Current price
1.65 USD -0.09 USD (-5.17%)
Last closed 1.69 USD
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Exchange NASDAQ
Capitalization 45 007 132 USD
Yield for 12 month -71.00 %
1Y
3Y
5Y
10Y
15Y
DRRX
21.11.2021 - 28.11.2021

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California. Address: 10260 Bubb Road, Cupertino, CA, United States, 95014-4166

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

6.75 USD

P/E ratio

Dividend Yield

Current Year

+8 548 000 USD

Last Year

+19 283 000 USD

Current Quarter

+1 827 000 USD

Last Quarter

+2 669 000 USD

Current Year

+6 831 000 USD

Last Year

+17 695 000 USD

Current Quarter

+1 538 000 USD

Last Quarter

+2 011 000 USD

Key Figures DRRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -31 541 000 USD
Operating Margin TTM -312.92 %
PE Ratio
Return On Assets TTM -41.74 %
PEG Ratio -0.46
Return On Equity TTM -196.94 %
Wall Street Target Price 6.75 USD
Revenue TTM 8 321 000 USD
Book Value 0.27 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -11.1 %
Dividend Yield
Gross Profit TTM 16 480 000 USD
Earnings per share -0.93 USD
Diluted Eps TTM -0.93 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin -279.77 %

Dividend Analytics DRRX

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History DRRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:10
Payout Ratio
Last Split Date 06.12.2022
Dividend Date

Stock Valuation DRRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 1.7502
Price Sales TTM 2.7805
Enterprise Value EBITDA -0.6032
Price Book MRQ 1.6164

Financials DRRX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators DRRX

For 52 weeks

0.47 USD 5.77 USD
50 Day MA 1.09 USD
Shares Short Prior Month 912 510
200 Day MA 1.37 USD
Short Ratio 8.63
Shares Short 1 053 197
Short Percent 2.97 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

441.58 USD Microsoft Corporation +0.8 (+0.18%)
Detailed analytics

ETF funds


S

SX7EEX

13.85 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) -0.35 (-2.26%)
Detailed analytics

Metals


Gold

2332.52 USD Gold +27.54 (+1.2%)
Detailed analytics